IRIS
D'INCALCI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.105
AS - Asia 9.045
EU - Europa 3.146
SA - Sud America 2.069
AF - Africa 191
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 4
Totale 28.573
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.820
SG - Singapore 5.630
BR - Brasile 1.734
CN - Cina 1.517
VN - Vietnam 799
FI - Finlandia 748
IE - Irlanda 511
DE - Germania 430
FR - Francia 318
IN - India 270
IT - Italia 241
GB - Regno Unito 221
NL - Olanda 204
HK - Hong Kong 197
AR - Argentina 130
CA - Canada 128
BD - Bangladesh 113
SE - Svezia 93
MX - Messico 75
IQ - Iraq 71
PL - Polonia 61
TR - Turchia 61
BE - Belgio 57
EC - Ecuador 56
RU - Federazione Russa 56
ZA - Sudafrica 54
ID - Indonesia 50
JP - Giappone 45
ES - Italia 43
CO - Colombia 38
UA - Ucraina 36
PK - Pakistan 31
CL - Cile 27
MA - Marocco 27
MY - Malesia 27
AE - Emirati Arabi Uniti 26
UZ - Uzbekistan 25
VE - Venezuela 25
SA - Arabia Saudita 24
PY - Paraguay 22
NG - Nigeria 20
PH - Filippine 19
KE - Kenya 18
TN - Tunisia 17
CZ - Repubblica Ceca 16
DO - Repubblica Dominicana 16
EG - Egitto 16
JM - Giamaica 16
LT - Lituania 16
IL - Israele 15
PA - Panama 15
PE - Perù 15
UY - Uruguay 15
JO - Giordania 14
DZ - Algeria 13
AZ - Azerbaigian 12
KZ - Kazakistan 12
NP - Nepal 11
LB - Libano 10
AT - Austria 9
AL - Albania 8
AU - Australia 8
PS - Palestinian Territory 8
TH - Thailandia 8
GR - Grecia 7
LV - Lettonia 7
NI - Nicaragua 7
PT - Portogallo 7
CR - Costa Rica 6
KR - Corea 6
RO - Romania 6
RS - Serbia 6
AO - Angola 5
BO - Bolivia 5
BY - Bielorussia 5
CH - Svizzera 5
KG - Kirghizistan 5
NO - Norvegia 5
SN - Senegal 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
DK - Danimarca 4
EE - Estonia 4
ET - Etiopia 4
GE - Georgia 4
HN - Honduras 4
LU - Lussemburgo 4
OM - Oman 4
XK - ???statistics.table.value.countryCode.XK??? 4
AM - Armenia 3
BH - Bahrain 3
CI - Costa d'Avorio 3
GT - Guatemala 3
IR - Iran 3
KH - Cambogia 3
PR - Porto Rico 3
SV - El Salvador 3
BN - Brunei Darussalam 2
Totale 28.531
Salva come PNG Salva come JPEG
Città #
Chandler 2.264
Singapore 2.151
Ashburn 1.742
San Jose 1.566
The Dalles 1.004
Helsinki 740
New York 684
Shanghai 683
Dublin 509
Princeton 461
Lawrence 460
Boardman 444
Dallas 440
Los Angeles 342
Paris 278
Ho Chi Minh City 266
Beijing 194
Amsterdam 182
Hong Kong 182
Hanoi 172
Santa Clara 162
São Paulo 147
Pune 142
Falkenstein 119
London 117
Buffalo 94
Seattle 73
Rio de Janeiro 68
Assago 58
Brussels 56
Munich 50
Phoenix 50
Brooklyn 49
Warsaw 49
Belo Horizonte 42
Haiphong 42
Frankfurt am Main 41
Chicago 39
Milan 38
Montreal 38
Orem 37
Wilmington 37
Da Nang 36
Boston 35
Curitiba 35
Chennai 34
Tokyo 34
Council Bluffs 32
Johannesburg 31
Mexico City 31
Stockholm 30
San Francisco 29
Brasília 28
Porto Alegre 27
Baghdad 26
Dhaka 24
Berlin 23
Toronto 23
Atlanta 21
Columbus 21
Tashkent 21
Denver 20
Guayaquil 20
Istanbul 20
Moscow 20
Biên Hòa 19
Charlotte 19
Guangzhou 18
Kuala Lumpur 18
Rome 18
Campinas 17
Guarulhos 17
Benin City 16
Hải Dương 16
Quito 15
Montevideo 14
San Mateo 14
Amman 13
Ankara 13
Kingston 13
Nairobi 13
Ninh Bình 13
Pasadena 13
Ribeirão Preto 13
Borås 12
Clifton 12
Erbil 12
Jakarta 12
Manaus 12
Manchester 12
Panama City 12
Thái Nguyên 12
Baku 11
Bogotá 11
Fortaleza 11
Lahore 11
New Delhi 11
Osasco 11
Salvador 11
Santiago 11
Totale 17.409
Salva come PNG Salva come JPEG
Nome #
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 142
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 115
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 114
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics 112
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 106
Mesothelioma. From research to clinical practice 101
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin 100
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment 100
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma 98
34. Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study 97
A Review of Trabectedin (ET-743): A Unique Mechanism of Action 94
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models 93
3-methyladenine-DNA-glycosylase and O-6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines 89
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 89
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 88
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors 88
A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera 87
A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging 87
A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma 86
A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 85
In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells 85
"The Art of Successful Publication" ECCO 13 workshop report 84
p21(WAF1)-derived peptides linked to an internalization peptide inhibit human cancer cell growth 84
A novel taxane active against an orthotopically growing human glioma xenograft 84
How Medicines are Born. The Imperfect Science of Drugs 84
Clinical pharmacokinetics of the new oral camptothecin gimatecan: The inter-patient variability is related to alpha(1)-acid glycoprotein plasma levels 82
The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism 82
A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia 82
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB 82
Reduced expression of the rock inhibitor rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells 81
COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC) 80
Tumor Associated Macrophages: toward a better understanding of their cancer driver capability in Malignant Pleural Mesothelioma. 80
A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma 79
Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue 79
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals 79
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences 79
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 78
Pharmacokinetics of concomitant cisplatin and paclitaxel administration by hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis 78
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells 78
Interferon-beta can induce progesterone receptors in human endometrial adenocarcinoma 78
Sequence-specific DNA alkylation of novel tallimustine derivatives 77
Pharmacokinetic of the novel oral camptothecin gimatecan in women with pre-treated advanced breast cancer 76
Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors 76
The combination of yondelis and cisplatin is synergistic against human tumor xenografts 76
Mechanisms of resistance to alkylating agents 76
Induction of resistance to Aplidin (R) in a human ovarian cancer cell line related to MDR expression 76
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts 75
DISTAMYCIN-A AND TALLIMUSTINE INHIBIT TBP BINDING AND BASAL IN-VITRO TRANSCRIPTION 75
A FILTER INCUBATION METHOD FOR THE DETERMINATION OF POTENTIALLY CROSSLINKABLE SITES IN DNA IN MAMMALIAN-CELLS 75
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia 75
A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers 75
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 74
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters 73
Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging 73
Pharmacokinetic study of trabectedin administered as 24-hour infusion in elderly patients with advanced soft tissue sarcoma (STS) treated according to the TR1US ISG study 73
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis 73
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 72
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 72
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY AND INDUCTION OF NOVEL IMMUNOGENICITY IN MURINE TUMOR-CELLS TREATED WITH METHYLATING AGENTS 72
The potential impact of marine compounds in the era of targeting therapies 71
Unique features of the mode of action of ET-743 71
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma 71
Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy 71
Structure elucidation of taxol metabolites by liquid chromatography mass spectrometry and species differences in taxol metabolism - Reply 71
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study 71
Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice 70
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus 70
Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles 70
The unique biological features of the marine product Yondelis? (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring 70
Are we close to the clinical development of novel drugs targeting telomeres and telomerase? 70
Genetic Instability Influences Drug Response in Cancer Cells 69
Pharmacokinetic of the novel oral camptothecin Gimatecan in patients with advanced or metastatic soft tissue sarcoma 69
Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine 69
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells 69
Sequential administration of temozolomide and fotemustine: Depletion of O-6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours 69
AN OPEN-LABEL, RANDOMIZED PHASE II STUDY ON TRABECTEDIN AND BEVACIZUMAB WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE (PPS) OVARIAN CANCER 69
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity 69
Modulation of gene transcription by natural products - A viable anticancer strategy 69
N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma 69
Pharmacological study on PEG-Asparaginase used in front-line treatment of children with acute lymphoblastic leukemia 69
Phase I clinical and pharmacokinetic (PK) study of oral (PO) methoxy-morpholino doxorubicin (PNU 152243) on a single intermittent schedule 68
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections 68
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models 68
L-asparagine-depletion: Another opinion - Response 68
Paclitaxel induces significant changes in epidoxorubicin distribution in mice 68
miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup 68
GEMCITABINE (G) AT FIXED DOSE RATE (FDR) INFUSION, COMBINED WITH CISPLATIN (C), IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A PHASE II STUDY WITH INCREMENTAL G DOSES 68
Trabectedin therapy for sarcomas 68
HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model 68
EPOC-experiences - conducting a multinational clinical trial on the pharmacology of doxorubicin in children with cancer 68
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin 67
Role of homologous recombination in trabectedin-induced DNA damage 67
Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study 67
Activation of TGF-Beta Pathway Through Mir-181a and Psmad-2 Overexpression Drives Resistance To Neoadjuvant Chemotherapy in High Grade Serous Advanced Ovarian Cancer 67
The Biological Connection Markup Language - a Data Format to Visualize, Annotate and Analyze Biological Pathways 67
DECREASED CYTOTOXIC EFFECTS OF DOXORUBICIN IN A HUMAN OVARIAN CANCER-CELL LINE EXPRESSING WILD-TYPE P53 AND WAF1/CIP1 GENES 67
Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study 67
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging 67
High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol (R)) in human plasma 67
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels 67
Totale 7.819
Salva come PNG Salva come JPEG
Categoria #
all - tutte 187.368
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 187.368
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 0 7
2021/2022244 2 4 0 7 1 0 0 7 19 5 67 132
2022/20236.459 1.028 151 587 747 428 615 5 690 1.151 575 412 70
2023/20243.814 333 311 940 283 106 679 113 195 39 176 366 273
2024/20254.849 121 16 21 98 128 615 255 271 1.022 1.228 579 495
2025/202613.181 2.014 895 618 1.257 390 687 4.140 544 737 843 537 519
Totale 28.612